Skip to main content

Advertisement

SpringerLink
Log in

A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie’s disease

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Peyronie’s disease (PD) is a superficial fibrosing disorder that causes penile deformity and can interfere with sexual intercourse and reproduction, as well as diminish quality of life. While the exact mechanism of PD is still being investigated, there is likely a genetic component to the predisposition to penile plaque formation. Ultimately, however, perturbations in normal wound healing and aberrant deposition of extracellular matrix components lead to fibrotic tissue deposition. Fibrosis in PD is regulated by a complex pathway of inflammatory and fibrotic mediators. Currently there are no treatments for PD that address an underlying cause or disease progression. In this review, we provide an overview of the known inflammatory and fibrotic mediators of PD and explore the pathophysiology of other human superficial fibrosing disorders to develop further insights into PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X (2011) A population-based study of Peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol 2011:282503. https://doi.org/10.1155/2011/282503

    Article  PubMed  PubMed Central  Google Scholar 

  2. Stuntz M, Perlaky A, Des Vignes F, Kyriakides T, Glass D (2016) The prevalence of Peyronie’s disease in the United States: a population-based study. PLoS One 11(2):e0150157. https://doi.org/10.1371/journal.pone.0150157

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U (2001) The prevalence of Peyronie’s disease: results of a large survey. BJU Int 88(7):727–730

    Article  CAS  Google Scholar 

  4. Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT (1991) The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol 146(4):1007–1009

    Article  CAS  Google Scholar 

  5. Gonzalez-Cadavid NF, Rajfer J (2005) Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie’s disease. Nat Clin Pract Urol 2(6):291–297. https://doi.org/10.1038/ncpuro0201

    Article  CAS  PubMed  Google Scholar 

  6. Nyberg LM Jr, Bias WB, Hochberg MC, Walsh PC (1982) Identification of an inherited form of Peyronie’s disease with autosomal dominant inheritance and association with Dupuytren’s contracture and histocompatibility B7 cross-reacting antigens. J Urol 128(1):48–51

    Article  Google Scholar 

  7. Willscher MK, Cwazka WF, Novicki DE (1979) The association of histocompatibility antigens of the B7 cross-reacting group with Peyronie’s disease. J Urol 122(1):34–35

    Article  CAS  Google Scholar 

  8. Rockey DC, Bell PD, Hill JA (2015) Fibrosis—a common pathway to organ injury and failure. N Engl J Med 373(1):96. https://doi.org/10.1056/NEJMc1504848

    Article  PubMed  Google Scholar 

  9. Rosenbloom J, Castro SV, Jimenez SA (2010) Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med 152(3):159–166. https://doi.org/10.7326/0003-4819-152-3-201002020-00007

    Article  PubMed  Google Scholar 

  10. Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X (2011) Prevalence, incidence, and treatments of Dupuytren’s disease in the United States: results from a population-based study. Hand (New York, NY) 6(2):149–158. https://doi.org/10.1007/s11552-010-9306-4

    Article  Google Scholar 

  11. Nugteren HM, Nijman JM, de Jong IJ, van Driel MF (2011) The association between Peyronie’s and Dupuytren’s disease. Int J Impot Res 23(4):142–145. https://doi.org/10.1038/ijir.2011.18

    Article  CAS  PubMed  Google Scholar 

  12. Shindel AW, Sweet G, Thieu W, Durbin-Johnson B, Rothschild J, Szabo R (2017) Prevalence of Peyronie’s disease-like symptoms in men presenting with dupuytren contractures. Sex Med 5(3):e135–e141. https://doi.org/10.1016/j.esxm.2017.06.001

    Article  PubMed  PubMed Central  Google Scholar 

  13. Alioto RJ, Rosier RN, Burton RI, Puzas JE (1994) Comparative effects of growth factors on fibroblasts of Dupuytren’s tissue and normal palmar fascia. J Hand Surg 19(3):442–452

    Article  CAS  Google Scholar 

  14. Badalamente MA, Hurst LC, Grandia SK, Sampson SP (1992) Platelet-derived growth factor in Dupuytren’s disease. J Hand Surg 17(2):317–323

    Article  CAS  Google Scholar 

  15. Badalamente MA, Sampson SP, Hurst LC, Dowd A, Miyasaka K (1996) The role of transforming growth factor beta in Dupuytren’s disease. J Hand Surg 21(2):210–215. https://doi.org/10.1016/s0363-5023(96)80102-x

    Article  CAS  Google Scholar 

  16. Bayat A, Alansar A, Hajeer AH, Shah M, Watson JS, Stanley JK, Ferguson MW, Ollier WE (2002) Genetic susceptibility in Dupuytren’s disease: lack of association of a novel transforming growth factor beta(2) polymorphism in Dupuytren’s disease. J Hand Surg (Edinburgh, Scotland) 27(1):47–49. https://doi.org/10.1054/jhsb.2001.0689

    Article  CAS  Google Scholar 

  17. Berndt A, Kosmehl H, Mandel U, Gabler U, Luo X, Celeda D, Zardi L, Katenkamp D (1995) TGF beta and bFGF synthesis and localization in Dupuytren’s disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochem J 27(12):1014–1020

    Article  CAS  Google Scholar 

  18. Gonzalez AM, Buscaglia M, Fox R, Isacchi A, Sarmientos P, Farris J, Ong M, Martineau D, Lappi DA, Baird A (1992) Basic fibroblast growth factor in Dupuytren’s contracture. Am J Pathol 141(3):661–671

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF (2004) Comparison of gene expression profiles between Peyronie’s disease and Dupuytren’s contracture. Urology 64(2):399–404. https://doi.org/10.1016/j.urology.2004.04.006

    Article  CAS  PubMed  Google Scholar 

  20. Bilgutay AN, Pastuszak AW (2015) Peyronie’s disease: a review of etiology, diagnosis, and management. Curr Sex Health Rep 7(2):117–131. https://doi.org/10.1007/s11930-015-0045-y

    Article  PubMed  PubMed Central  Google Scholar 

  21. Kim SK, Ioannidis JPA, Ahmed MA, Avins AL, Kleimeyer JP, Fredericson M, Dragoo JL (2018) Two genetic variants associated with plantar fascial disorders. Int J Sports Med 39(4):314–321. https://doi.org/10.1055/s-0044-100280

    Article  CAS  PubMed  Google Scholar 

  22. Dolmans GH, de Bock GH, Werker PM (2012) Dupuytren diathesis and genetic risk. J Hand Surg 37(10):2106–2111. https://doi.org/10.1016/j.jhsa.2012.07.017

    Article  Google Scholar 

  23. Martinez MA, Ferrando D, Cordero PJ (1997) Idiopathic pulmonary fibrosis and Peyronie’s disease. Arch Bronconeumol 33(10):549–550

    Article  CAS  Google Scholar 

  24. Lyles KW, Gold DT, Newton RA, Parekh S, Shipp KM, Pieper CF, Krishan R, Carson CC 3rd (1997) Peyronie’s disease is associated with Paget’s disease of bone. J Bone Miner Res 12(6):929–934. https://doi.org/10.1359/jbmr.1997.12.6.929

    Article  CAS  PubMed  Google Scholar 

  25. Akbal C, Tanidir Y, Ozgen MB, Simsek F (2008) Erectile dysfunction and Peyronie’s disease in patient with retroperitoneal fibrosis. Int Urol Nephrol 40(4):971–975. https://doi.org/10.1007/s11255-008-9381-4

    Article  PubMed  Google Scholar 

  26. Chen TY, Zahran AR, Carrier S (2001) Penile curvature associated with scleroderma. Urology 58(2):282

    Article  CAS  Google Scholar 

  27. Chen DL, Chong AH, Green J, Orchard D, Williams R, Clemens L (2006) A novel case of polyfibromatosis and interstitial granulomatous dermatitis with arthritis. J Am Acad Dermatol 55(2 Suppl):S32–S37. https://doi.org/10.1016/j.jaad.2006.02.038

    Article  PubMed  Google Scholar 

  28. Simeon CP, Fonollosa V, Vilardell M, Ordi J, Solans R, Lima J (1994) Impotence and Peyronie’s disease in systemic sclerosis. Clin Exp Rheumatol 12(4):464

    CAS  PubMed  Google Scholar 

  29. Ordi J, Selva A, Fonollosa V, Vilardell M, Jordana R, Tolosa C (1990) Peyronie’s disease in systemic sclerosis. Ann Rheum Dis 49(2):134–135

    Article  CAS  Google Scholar 

  30. Ventimiglia E, Capogrosso P, Colicchia M, Boeri L, Serino A, La Croce G, Russo A, Capitanio U, Briganti A, Cantiello F, Mirone V, Damiano R, Montorsi F, Salonia A (2015) Peyronie’s disease and autoimmunity-a real-life clinical study and comprehensive review. J Sex Med 12(4):1062–1069. https://doi.org/10.1111/jsm.12825

    Article  PubMed  Google Scholar 

  31. Pastuszak AW, Rodriguez KM, Solomon ZJ, Kohn TP, Lipshultz LI, Eisenberg ML (2018) Increased risk of incident disease in men with Peyronie’s disease: analysis of U.S. claims data. J Sex Med 15(6):894–901. https://doi.org/10.1016/j.jsxm.2018.04.640

    Article  PubMed  Google Scholar 

  32. Lue TF (2002) Peyronie’s disease: an anatomically-based hypothesis and beyond. Int J Impot Res 14(5):411–413. https://doi.org/10.1038/sj.ijir.3900876

    Article  CAS  PubMed  Google Scholar 

  33. Meng XM, Nikolic-Paterson DJ, Lan HY (2016) TGF-beta: the master regulator of fibrosis. Nat Rev Nephrol 12(6):325–338. https://doi.org/10.1038/nrneph.2016.48

    Article  CAS  PubMed  Google Scholar 

  34. Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214(2):199–210. https://doi.org/10.1002/path.2277

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Border WA, Noble NA (1994) Transforming growth factor beta in tissue fibrosis. N Engl J Med 331(19):1286–1292. https://doi.org/10.1056/nejm199411103311907

    Article  CAS  PubMed  Google Scholar 

  36. Border WA, Ruoslahti E (1992) Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Investig 90(1):1–7. https://doi.org/10.1172/jci115821

    Article  CAS  PubMed  Google Scholar 

  37. El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF (1997) An animal model of Peyronie’s-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 158(6):2284–2290

    Article  CAS  Google Scholar 

  38. El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF (1997) Peyronie’s disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 158(4):1391–1394

    Article  CAS  Google Scholar 

  39. Ryu JK, Kim WJ, Choi MJ, Park JM, Song KM, Kwon MH, Das ND, Kwon KD, Batbold D, Yin GN, Suh JK (2013) Inhibition of histone deacetylase 2 mitigates profibrotic TGF-beta1 responses in fibroblasts derived from Peyronie’s plaque. Asian J Androl 15(5):640–645. https://doi.org/10.1038/aja.2013.61

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Gonzalez-Cadavid NF, Magee TR, Ferrini M, Qian A, Vernet D, Rajfer J (2002) Gene expression in Peyronie’s disease. Int J Impot Res 14(5):361–374. https://doi.org/10.1038/sj.ijir.3900873

    Article  CAS  PubMed  Google Scholar 

  41. Giannandrea M, Parks WC (2014) Diverse functions of matrix metalloproteinases during fibrosis. Dis Models Mech 7(2):193–203. https://doi.org/10.1242/dmm.012062

    Article  CAS  Google Scholar 

  42. Pardo A, Selman M (2006) Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc 3(4):383–388. https://doi.org/10.1513/pats.200601-012TK

    Article  CAS  PubMed  Google Scholar 

  43. Van de Water L (1997) Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie’s disease. J Urol 157(1):306–310

    Article  Google Scholar 

  44. El-Sakka AI, Salabas E, Dincer M, Kadioglu A (2013) The pathophysiology of Peyronie’s disease. Arab J Urol 11(3):272–277. https://doi.org/10.1016/j.aju.2013.06.006

    Article  PubMed  PubMed Central  Google Scholar 

  45. Moreland RB, Nehra A (2002) Pathophysiology of Peyronie’s disease. Int J Impot Res 14(5):406–410. https://doi.org/10.1038/sj.ijir.3900875

    Article  CAS  PubMed  Google Scholar 

  46. Liu RM, Desai LP (2015) Reciprocal regulation of TGF-beta and reactive oxygen species: a perverse cycle for fibrosis. Redox Biol 6:565–577. https://doi.org/10.1016/j.redox.2015.09.009

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Vernet D, Nolazco G, Cantini L, Magee TR, Qian A, Rajfer J, Gonzalez-Cadavid NF (2005) Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease. Biol Reprod 73(6):1199–1210. https://doi.org/10.1095/biolreprod.105.041038

    Article  CAS  PubMed  Google Scholar 

  48. Huleihel M, Douvdevani A, Segal S, Apte RN (1990) Regulation of interleukin 1 generation in immune-activated fibroblasts. Eur J Immunol 20(4):731–738. https://doi.org/10.1002/eji.1830200404

    Article  CAS  PubMed  Google Scholar 

  49. Pryor JP, Ralph DJ (2002) Clinical presentations of Peyronie’s disease. Int J Impot Res 14(5):414–417. https://doi.org/10.1038/sj.ijir.3900877

    Article  CAS  PubMed  Google Scholar 

  50. Sasaki K, Hattori T, Fujisawa T, Takahashi K, Inoue H, Takigawa M (1998) Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. J Biochem 123(3):431–439

    Article  CAS  Google Scholar 

  51. Bivalacqua TJ, Champion HC, Hellstrom WJ (2002) Implications of nitric oxide synthase isoforms in the pathophysiology of Peyronie’s disease. Int J Impot Res 14(5):345–352. https://doi.org/10.1038/sj.ijir.3900872

    Article  CAS  PubMed  Google Scholar 

  52. Mulhall JP, Thom J, Lubrano T, Shankey TV (2001) Basic fibroblast growth factor expression in Peyronie’s disease. J Urol 165(2):419–423. https://doi.org/10.1097/00005392-200102000-00016

    Article  CAS  PubMed  Google Scholar 

  53. Lambert E, Dasse E, Haye B, Petitfrere E (2004) TIMPs as multifacial proteins. Crit Rev Oncol/Hematol 49(3):187–198. https://doi.org/10.1016/j.critrevonc.2003.09.008

    Article  Google Scholar 

  54. Davila HH, Magee TR, Zuniga FI, Rajfer J, Gonzalez-Cadavid NF (2005) Peyronie’s disease associated with increase in plasminogen activator inhibitor in fibrotic plaque. Urology 65(4):645–648. https://doi.org/10.1016/j.urology.2005.01.010

    Article  PubMed  Google Scholar 

  55. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, Saito Y, Johnson RS, Kretzler M, Cohen CD, Eckardt KU, Iwano M, Haase VH (2007) Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Investig 117(12):3810–3820. https://doi.org/10.1172/jci30487

    Article  CAS  PubMed  Google Scholar 

  56. Sanchez-Elsner T, Botella LM, Velasco B, Corbi A, Attisano L, Bernabeu C (2001) Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem 276(42):38527–38535. https://doi.org/10.1074/jbc.M104536200

    Article  CAS  PubMed  Google Scholar 

  57. Amara N, Goven D, Prost F, Muloway R, Crestani B, Boczkowski J (2010) NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. Thorax 65(8):733–738. https://doi.org/10.1136/thx.2009.113456

    Article  PubMed  PubMed Central  Google Scholar 

  58. Sancho P, Mainez J, Crosas-Molist E, Roncero C, Fernandez-Rodriguez CM, Pinedo F, Huber H, Eferl R, Mikulits W, Fabregat I (2012) NADPH oxidase NOX4 mediates stellate cell activation and hepatocyte cell death during liver fibrosis development. PLoS One 7(9):e45285. https://doi.org/10.1371/journal.pone.0045285

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Poli G, Parola M (1997) Oxidative damage and fibrogenesis. Free Radic Biol Med 22(1–2):287–305

    Article  CAS  Google Scholar 

  60. Paulis G, Romano G, Paulis L, Barletta D (2017) Recent pathophysiological aspects of Peyronie’s disease: role of free radicals, rationale, and therapeutic implications for antioxidant treatment-literature review. Adv Urol 2017:4653512. https://doi.org/10.1155/2017/4653512

    Article  PubMed  PubMed Central  Google Scholar 

  61. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425(6958):577–584. https://doi.org/10.1038/nature02006

    Article  CAS  PubMed  Google Scholar 

  62. Miyazono K, Kusanagi K, Inoue H (2001) Divergence and convergence of TGF-beta/BMP signaling. J Cell Physiol 187(3):265–276. https://doi.org/10.1002/jcp.1080

    Article  CAS  PubMed  Google Scholar 

  63. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R (2003) BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9(7):964–968. https://doi.org/10.1038/nm888

    Article  CAS  PubMed  Google Scholar 

  64. Chen G, Deng C, Li YP (2012) TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 8(2):272–288. https://doi.org/10.7150/ijbs.2929

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Nohe A, Keating E, Knaus P, Petersen NO (2004) Signal transduction of bone morphogenetic protein receptors. Cell Signal 16(3):291–299

    Article  CAS  Google Scholar 

  66. Jinnin M (2010) Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol 37(1):11–25. https://doi.org/10.1111/j.1346-8138.2009.00738.x

    Article  CAS  PubMed  Google Scholar 

  67. Dolmans GH, Werker PM, de Jong IJ, Nijman RJ, Wijmenga C, Ophoff RA (2012) WNT2 locus is involved in genetic susceptibility of Peyronie’s disease. J Sex Med 9(5):1430–1434. https://doi.org/10.1111/j.1743-6109.2012.02704.x

    Article  CAS  PubMed  Google Scholar 

  68. Kavian N, Servettaz A, Weill B, Batteux F (2012) New insights into the mechanism of notch signalling in fibrosis. Open Rheumatol J 6:96–102. https://doi.org/10.2174/1874312901206010096

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Dees C, Tomcik M, Zerr P, Akhmetshina A, Horn A, Palumbo K, Beyer C, Zwerina J, Distler O, Schett G, Distler JH (2011) Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis 70(7):1304–1310. https://doi.org/10.1136/ard.2010.134742

    Article  CAS  PubMed  Google Scholar 

  70. Rohatgi R, Milenkovic L, Corcoran RB, Scott MP (2009) Hedgehog signal transduction by Smoothened: pharmacologic evidence for a 2-step activation process. Proc Natl Acad Sci USA 106(9):3196–3201. https://doi.org/10.1073/pnas.0813373106

    Article  PubMed  Google Scholar 

  71. Horn A, Palumbo K, Cordazzo C, Dees C, Akhmetshina A, Tomcik M, Zerr P, Avouac J, Gusinde J, Zwerina J, Roudaut H, Traiffort E, Ruat M, Distler O, Schett G, Distler JH (2012) Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum 64(8):2724–2733. https://doi.org/10.1002/art.34444

    Article  CAS  PubMed  Google Scholar 

  72. Clevers H, Nusse R (2012) Wnt/beta-catenin signaling and disease. Cell 149(6):1192–1205. https://doi.org/10.1016/j.cell.2012.05.012

    Article  CAS  PubMed  Google Scholar 

  73. Beyer C, Schramm A, Akhmetshina A, Dees C, Kireva T, Gelse K, Sonnylal S, de Crombrugghe B, Taketo MM, Distler O, Schett G, Distler JH (2012) beta-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis 71(5):761–767. https://doi.org/10.1136/annrheumdis-2011-200568

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

A.W.P. is a National Institutes of Health K08 Scholar supported by a Mentored Career Development Award (K08DK115835-01) from the National Institute of Diabetes and Digestive and Kidney Diseases. This work is also supported in part through a Urology Care Foundation Rising Stars in Urology Award (to A.W.P.).

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery, Center for Reconstructive Urology and Men’s Health, University of Utah School of Medicine, 30 N 1900 E, Rm # 3B420, Salt Lake City, UT, 84132, USA

    Darshan P. Patel, Michael B. Christensen, James M. Hotaling & Alexander W. Pastuszak

Authors
  1. Darshan P. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael B. Christensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James M. Hotaling
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexander W. Pastuszak
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DPP: literature review, manuscript writing/editing, critical review, approval of final manuscript. MBC: literature review, manuscript writing/editing, critical review, approval of final manuscript. JMH: manuscript writing/editing, critical review, approval of final manuscript. AWP: literature review, manuscript writing/editing, critical review, approval of final manuscript.

Corresponding author

Correspondence to Alexander W. Pastuszak.

Ethics declarations

Conflict of interest

DP Patel: None. MB Christensen: None. JM Hotaling: Dr. Hotaling receives research and fellowship support from Boston Scientific and Endo Pharmaceuticals. He holds leadership roles/equity interest in Nanonc, StreamDx, and Andro360 which are all early stage startup companies. AW Pastuszak: Dr. Pastuszak is an advisor to Endo Pharmaceuticals, Boston Scientific, and Antares Pharmaceuticals, and a speaker for Endo Pharmaceuticals and Bayer AG. He is a consultant and receives research and fellowship support from Endo Pharmaceuticals. He holds a leadership position with Woven Health, of which he is also a founder. As this is a review article, no research involving human participants and/or animals was carried out and no informed consent was needed.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patel, D.P., Christensen, M.B., Hotaling, J.M. et al. A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie’s disease. World J Urol 38, 253–261 (2020). https://doi.org/10.1007/s00345-019-02815-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-019-02815-6

Keywords

Search

Navigation